Noteworthy, treatment with fenofibrate, a PPAR-α agonist that specifically targets AD, exerts beneficial effects on macrovascular disease in T2DM patients with AD, but also confers vascular protection against retinal, renal and lower-limb microangiopathies[3,4,9-11]. This evidence concerns the gene PPARA and type 2 diabetes mellitus.